Abstract 5485
Background
Non-small cell lung cancer (NSCLC), the most common subtype of lung cancer, is characterized by low response rates and a poor prognosis. The majority of patients are diagnosed in advanced stages, where chemotherapy remains the gold standard of treatment. However, the resistance has been associated to cancer stem cells (CSCs), a highly tumorigenic subpopulation of cells with the ability to grow as spheres in non-adherent conditions. The aim of this study was to discover novel therapeutic strategies through screening platforms in order to target CSCs population.
Methods
High-throughput screening with commercial chemical libraries (Prestwick and Myria) was performed, comparing cytotoxic effect in monolayer cells vs. lung-tumorspheres derived from 8 resected NSCLC patients and 11 NSCLC cell lines. Compounds were added per triplicates at different concentrations (0.01 to 50 µM). Cell viability was measured after 48h using MTS Assay. Consecutively, 8 tumors were induced by inoculating resected NSCLC patient and H1650 lung-tumor-spheroids in NOD/SCID mice. Selected drugs were administered intraperitoneally (3 times a week, 100 mg/kg). Characterization of the inhibition pathway involved in the mechanism of action of these drugs was performed by RT-qPCR.
Results
Three drugs of the commercial chemical libraries (DSF, Compound 1 and Compound 2) were identified with greater cytotoxic potential against lung tumorspheres, compared to a poor or null effect on monolayer cells. These results were validated in vivo, which demonstrated the capacity of these drugs to inhibit tumor growth in mice treated respect to the control (Table). We are currently characterizing the signaling pathways involved in the mechanism of action of these drugs.
Conclusions
Our findings reveal that these drugs can inhibit CSCs like properties, as evidenced in the lung tumorspheres in vitro and in vivo assays. Therefore, these compounds could be a promising targeted therapy as potential inhibitors of lung CSCs.Table: 1889P
Percentage of tumor reduction in the mice treated respect to the control
| Mice (Line/Patient) | Tumor Volume (mm3) | Tumor Reduction (%) |
|---|---|---|
| H1650_CNT | 1593,11 | |
| H1650_DSF | 541,44 | 66.02 |
| H1650_Compound 1 | 483,72 | 69.64 |
| H1650_Compound 2 | 276,98 | 82.62 |
| Patient_CNT | 1645,68 | |
| Patient_DSF | 490 | 70,23 |
| Patient Compound 1 | 721,56 | 56,16 |
| Patient Compound 2 | 1020 | 38,02 |
Clinical trial identification
Legal entity responsible for the study
Fundación para la Investigación Hospital General Universitario de Valencia.
Funding
Supported by ISCIII (P12-02838 / FIS P15-00573).
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract